All In Biotech

Drug Trial Radar · NCT05054348

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion, and Dose-Randomization Study of IO 108 as Monotherapy and in Combination With Either Pembrolizumab or Cemiplimab in Adult Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

91

Actual

Start

Sep 30, 2021

Primary completion

Apr 29, 2024

Study completion May 31, 2024

Sponsor

Lead sponsor
Immune-Onc TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Sep 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the clinical trial is to learn about safety, tolerability and preliminary efficacy of IO-108 as monotherapy or in combination with a PD-1 inhibitor in patients with advanced, metastatic solid tumors, and to find a dose of IO-108 that is safe and efficacious to be tested in patients with various solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

  • IO-108Biological

    IO-108 given as monotherapy

  • IO-108 + pembrolizumab combination therapyBiological

    IO-108 and fixed dose pembrolizumab combination therapy

  • IO-108 + cemiplimab combination therapyBiological

    IO-108 and fixed dose cemiplimab combination therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent and serious adverse events in patients treated with IO-108 and IO-108+pembrolizumabTime frame: From first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment date or disease progression whichever is earlier
  2. Determine MTD (maximum tolerated dose) through assessment of dose-limiting toxicities (DLT)Time frame: From the first dose of IO-108 until 21 days post-treatment
  3. Assess safety and tolerability of the IO-108 RP2D as monotherapy or in combination with either pembrolizumab or cemiplimab in patients with solid tumorsTime frame: From the first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment or disease progression, whicheer is earlier

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC-HOPE (140) (USOR SITE)

    Tucson, Arizona

  • Beverly HIlls Cancer Center (129)

    Beverly Hills, California

  • Rocky Mountain Cancer Centers, LLP (141) (USOR SITE)

    Lone Tree, Colorado

  • University of Florida (125)

    Gainesville, Florida

  • Florida Cancer Specialists (134)

    Lake Mary, Florida

  • Memorial Cancer Institute (146)

    Pembroke Pines, Florida

  • Florida Cancer Specialists & Research Institute (103)

    Sarasota, Florida

  • Hematology Oncology (136)

    Stuart, Florida

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center (123)

    Indianapolis, Indiana

  • Maryland Oncology Hematology, PA (145) (USOR SITE)

    Columbia, Maryland

  • Karmanos Cancer Institute (126)

    Detroit, Michigan

  • St. Vincent - Frontier Cancer Center (135)

    Billings, Montana

  • NYU Langone Health (131)

    New York, New York

  • Carolina BioOncology (102)

    Huntsville, North Carolina

  • Gabrail Cancer Center (128)

    Canton, Ohio

  • Oncology Hematology Care Clinical Trials, LLC (144) (USOR SITE)

    Cincinnati, Ohio

  • Providence Cancer Institute (104)

    Portland, Oregon

  • UPMC Hillman Cancer Center (105)

    Pittsburgh, Pennsylvania

  • Texas Oncology - Austin (142) (USOR SITE)

    Austin, Texas

  • Texas Oncology - Baylor Charles A. (143) (USOR SITE)

    Dallas, Texas

  • MD Anderson Cancer Center (101)

    Houston, Texas

  • Oncology Consultants, P.A. (138)

    Houston, Texas

  • NEXT Oncology-Virginia (121)

    Fairfax, Virginia

  • Swedish Cancer Institute (147)

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.